CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

CureMatch Recognized as Best Artificial Intelligence (AI) Company in Healthcare

CureMatch Recognized as Best Artificial Intelligence (AI) Company in Healthcare
AwardsEvents

CureMatch CEO as Featured Healthcare & AI Speaker at LES Event in San Diego

FOR IMMEDIATE RELEASE

SAN DIEGO, CA – July 12, 2018 – CureMatch, Inc. has been recognized as having the “Best AI-based Solution for Healthcare” by AI Breakthrough, an independent organization that recognizes the top companies, technologies, and products in the global Artificial Intelligence (AI) market. The CureMatch precision medicine technology utilizes machine learning features and rules-based decision support to offer ranked combination cancer treatment options and has succeeded in pushing ingenuity to be identified as one of the best AI solutions in 2018.

The AI Breakthrough Awards program attracted over 2,500 nominations from over 15 different countries, and winning companies were selected based on a variety of criteria, including the most innovative and technologically advanced products and services. CureMatch is one of only 31 award winners, with the “Best Overall AI Company” award given to Google.

“The global AI market is expected to be worth over seven billion dollars this year, and the industry is growing exponentially with numerous exciting technological developments progressing daily,” said James Johnson, managing director at AI Breakthrough. “With this amazing rate of market growth and development, AI Breakthrough is determined to recognize the standout AI solutions and companies.”

Best-AI-Artificial Intelligence-Breakthrough-award-healthcare

“CureMatch is thrilled to be highlighted as an AI visionary in healthcare, as the cure for cancer lies in technology,” stated Stephane Richard, Ph.D., CEO of CureMatch. “Oncologists around the globe, regardless of proximity to top cancer research centers, can receive world class therapeutic decision support with CureMatch.”

CureMatch CEO, Stephane Richard, Ph.D., is also a featured speaker at the Healthcare and Artificial Intelligence event by the Licensing Executives Society (LES). Sponsored by the UC San Diego’s Office of Innovation and Commercialization, Sanford Consortium for Regenerative Medicine, and Knobbe Martens, the presentation will cover specific perspectives and trends in the nascent yet expanding arena of AI-based healthcare.

Registration is open ($25 non-member) for this event on Thursday, July 12 starting at 6pm at the Roth Auditorium in La Jolla, CA.

Click for event details.

###

About AI Breakthrough
Part of the Tech Breakthrough Awards organization, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies, and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including AI Platforms, Robotics, Business Intelligence, AI Hardware, NLP, Vision, Biometrics, industry vertical AI applications and more. For more information visit AIBreakthroughAwards.com

About Licensing Executives Society (LES)
LES (USA & Canada) is a member society of the Licensing Executives Society International, Inc. (LESI), with a worldwide membership of over 9,000 professionals across 32 national societies located in more than 90 countries. For more than 50 years, LES has been the leading association for intellectual property, technology, and business development professionals to achieve professional and personal success.

LES-san_diego_chapter_logo

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. Utilizing proprietary algorithms to analyze over 4.5 million combinations of commonly used as well as newly approved cancer treatments found in massive pharmacological and clinical databases,  CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations and improve the precision of cancer treatment recommendations. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, molecular and cell biology. For more information, visit https://www.curematch.com

 

Media Contact
Name: Larissa Anderson
Company: CureMatch
Phone: 858-859-2873
Email: press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data